- A gene therapy company 4D Molecular Therapeutics (FDMT) has priced its upsized IPO of 8.4M shares of common stock (from 7M) at $23.00/share, for expected gross proceeds of $193.2M.
- Underwriters' over-allotment is an additional 1.26M shares.
- Trading kicks off today.
- Goldman Sachs, BofA Securities and Evercore are acting as book-running managers.
- Closing date is December 15.
- https://seekingalpha.com/news/3643606-4d-molecular-therapeutics-prices-upsized-ipo-23
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.